The FDA will hold its public meeting on PDUFA VIII on Sept. 16. Aiming to encourage companies to conduct Phase 1 development in the U.S., the FDA has proposed offering qualifying drugs a 50% reduction in the application fee, roughly $2.3 million in savings at current rates. I support the objective but question the means.…
